forked from tiroshlab/lab-book
-
Notifications
You must be signed in to change notification settings - Fork 0
Expand file tree
/
Copy path03-specificProjects.Rmd
More file actions
19 lines (13 loc) · 1.76 KB
/
03-specificProjects.Rmd
File metadata and controls
19 lines (13 loc) · 1.76 KB
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
# Specific Projects {#projects}
**Alissa**
My two main projects are 1) Modeling ITH in cancer cell lines with a focus on dynamics, differential drug sensitivity, and cancer cell-cancer cell interactions in HNSCC (with Rotem). 2) Spatial transcriptomics of GBM (in collaboration with the Suva Lab).
**Rony**
My thesis focuses on GBM intra-tumor heterogeneity, for which I have 3 projects in collaboration with Mario Suva’s lab at MGH: 1) modeling the GBM states in cancer cell lines and a mouse model of GBM, 2) exploring the GBM microenvironment cell-cell interactions in regards to the cellular states, and 3) targeting the GBM states as a therapeutic approach for GBM.
**Mike**
My work concerns deconvolution of bulk RNA-seq data to identify signatures of tumour subpopulations or cell states. My current project focuses on distinguishing EMT (or partial EMT) from stromal cells in bulk transcriptomes.
**Michael**
My work broadly focuses on ITH in head and neck cancer. In collaboration with Sid Puram’s lab I analyse scRNASeq data from patients with oropharyngeal, laryngeal and oral cavity cancer in order to find tumour genetic subclones and functional metaprograms in the cancer cells and microenvironment.
**Noam H**
My work is to do a regulatory follow up to lab discoveries on chromatin organization level using single cell ATAC-seq on two main ITH projects: 1) head and neck cancer 2) GBM.
**Julie**
My work focuses on understanding expression heterogeneity in gliomas. I analyse primarily scRNA-seq data from the Suva lab to 1) define the subpopulations of cancer cells that exist in different glioma types, 2) understand the emergence of these subpopulations as a function of cell lineage, genetics and the TME and 3) revisit the distinctions between glioma types.